

## **DAFTAR PUSTAKA**

1. Agus D. Pendekatan Holistik terhadap Skizofrenia. Majalah Psikiatri. Jakarta: Majalah Psikiatri; 2005.
2. Stuart G. Buku Saku Keperawatan Jiwa. Jakarta: Buku Kedokteran EGC; 2006.
3. Linden M, Qodemann F, Qaebel W, Kiipke W, Mutter P, Spahn FM, et al. A Prospective Study of Factors Influencing Adherence to a Continuous Neuroleptic Treatment Program in Schizophrenia Patients During 2 Years. 2001;27(4):585–96.
4. Badan Penelitian dan Pengembangan. Riset Kesehatan Dasar 2013. Jakarta; 2013.
5. Nantingkaseh L. Skizofrenia dan Gangguan Psikotik Lainnya. Jakarta; 2007.
6. Chisholm-Burns MA, Wells B, Schwinghammer T, Malone PM, Kolesar JM, Rotschafer JC, et al. Pharmacotherapy: Principles & Practice. New York: McGraw-Hill; 2008.
7. Cascade E, Kalali AH, Mehra S, Meyer JM. Real-world Data on Atypical Antipsychotic Medication Side Effects. Psychiatry (Edgmont). 2010;7(7):9–12.
8. Barnes TRE, Paton C. Antipsychotic Polypharmacy in Schizophrenia. CNS Drugs. 2011;25(5):383–99.

9. Sadock BJ, Sadock VA. Kaplan & Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2007.
10. Yosep I. Proses Terjadinya Gangguan Jiwa, Skizofrenia sebagai Bentuk Gangguan Jiwa [Internet]. 2008 [cited 2014 Nov 6]. Available from: <http://resources.unpad.ac.id/unpadcontent/uploads/>
11. First M, Tasman A. DSM-IV-TR Mental Disorder Diagnosis. Schizophrenia: Etiology and Treatment. London: Wiley; 2004.
12. Halgin R, Whitbourne, Susan K. Psikologi Abnormal: Perspektif Klinis pada Gangguan Psikologis. 6th ed. Jakarta: Salemba Humanika; 2010.
13. Cardno AG, Gottesman II. Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. Am J Med Genet. 2000;97(1):12–7.
14. Walsh T, McClellan J, McCarthy S, Addington A, Pierce S, Cooper G, et al. Rare Structural Variants Disrupt Multiple Genes in Neurodevelopmental Pathways in Schizophrenia. Science (80- ). 2008;320(5875):539–43.
15. Semiu Y. OFM Kesehatan Mental. 3rd ed. Yogyakarta: Kanisius; 2006.
16. Nevid J, Rathus S, Greene B. Psikologi Abnormal. Jakarta: Erlangga; 2005.
17. Roth BL, Meltzer HY. The Role of Serotonin in Schizophrenia [Internet]. 2000 [cited 2015 Feb 8]. Available from: <http://www.acnp.org/g4/GN401000117/CH115.html>

18. Sadock BJ, Sadock VA. Kaplan & Sadock: Buku Ajar Psikiatri Klinis. 2nd ed. Muttaqin H, Sihombing RNE, editors. Jakarta: Penerbit Buku Kedokteran EGC; 2010.
19. Kazadi N. Factors Associated with Relaps in Schizophrenia. Jakarta: Rineka Cipta; 2008.
20. Durrand V, Barlow D. Essentials of Abnormal Psychology. Yogyakarta: Pustaka Pelajar; 2007.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington DC: American Psychiatry Publishing Inc.; 2000.
22. Hawari D. Pendekatan Holistik pada Gangguan Jiwa Skizofrenia. Jakarta: FKUI; 2001.
23. Lehman AF, Lieberman J a, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice Guideline for the Treatment of Patients With Schizophrenia Second Edition. Am J Psychiatry. 2010;161:Suppl 1–56.
24. Syarif A, Estuningtyas A, Setiawati A, Muchtar A, Arif A, Bahry B, et al. Farmakologi dan Terapi. Jakarta: Departemen Farmakologi dan Terapeutik FKUI; 2007.
25. Lieberman J, Murray R. The Outcome of Psychotic Illness. Comprehensive Care of Schizophrenia: A Text Book of Clinical Management. London: Martin Dunitz Ltd.; 2001.

26. Wells B, Dipiro J, Schwinghammer T, Dipiro C. Pharmacotherapy Handbook. Pharmacotherapy Handbook. New York: McGraw-Hill; 2009. 719-725 p.
27. The Texas Departement of State Health Service. TIMA Algorithm for Antipsychotic Treatment in Schizophrenia. Pharmacotherapy: Principles & Practice. New York: McGraw-Hill; 2008.
28. Brunton LL, Lazo JS, Parker KL. Goodman and Gilman's The Pharmacological Basis of Therapeutics. Eleventh. New York: McGraw-Hill; 2006.
29. Alan F, Charles B. Essentials of Clinical Psychopharmacology. Washington DC: American Psychiatry Publishing Inc.; 2001.
30. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: A meta-analysis of randomized controlled trials. *Schizophr Bull*. 2009;35(2):443–57.
31. Faries D, Ascher-Svanum H, Zhu B, Correll C, Kane J. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. *BMC Psychiatry*. 2005;5:26.
32. Bastaman T. Skizofrenia: Dari Remisi ke Fungsi. *Maj Jiwa*. 2006;3(Juli):vii – viii.
33. Reverger MJ. Perbandingan Performa Fungsi Pasien Skizofrenia yang Mendapat Terapi Tunggal dengan Terapi Kombinasi Antipsikotika di

- Rumah Sakit Cipto Mangunkusumo (Periode Desember 2011-Mei 2012).  
Universitas Indonesia; 2012.
34. Madiyono B, Mz SM, Sastroasmoro S, Budiman I, Purwanto SH. Perkiraan Besar Sampel. In: Sastroasmoro S, Ismael S, editors. Dasar-Dasar Metodologi Penelitian Klinis. Kedua. Jakarta: Sagung Seto; 2002.
35. Seeman M V. Gender differences in the prescribing of antipsychotic drugs. *Am J Psychiatry*. 2004;161(8):1324–33.
36. Laloo R, Sheiham A. Risk factors for childhood major and minor head and other injuries in a nationally representative sample. *Injury*. 2003;34(4):261–6.
37. Schizophrenia [Internet]. World Health Organizaton. 2014 [cited 2014 Jan 1]. Available from: [http://www.who.int/mental\\_health/management/schizophrenia/en/](http://www.who.int/mental_health/management/schizophrenia/en/)
38. Castle DJ, McGrath J. Women and Schizophrenia. Castle DJ, McGrath J, Kulkarni J, editors. London: Cambridge University Press; 2000.
39. Sira I. Karakteristik Skizofrenia di Rumah Sakit Khusus Alianyang Pontianak Periode 1 Januari - 31 Desember 2009. Universitas Tanjungpura; 2011.
40. Oktovina MN. Evaluasi Rejimen Obat Pasien Schizophrenia pada Unit Rawat Jalan dan Rawat Inap Setelah Uji Coba Kebijakan INA-DRG di Rumah Sakit Jiwa Dr. Soeharto Heerdjan Jakarta. [Depok]: Universitas Indonesia; 2009.

41. Michael R, Phillips, Yongyun LT, Stroup S, Xin L. Causes of Schizophrenia Reported by Patients' Family Members in China. *Br J Psychiatry*. 2000;177:20–5.
42. Savioli WK. The Relationship Between Perceived Stress and Smoking: Focusing on Schizophrenia and Comparative Sub-Groups Diagnosed with Mental Illness. Cleveland State University; 2009.
43. Lesmanawati DAS. Analisis Efektivitas Biaya Penggunaan Terapi Antipsikotik pada Pasien Skizofrenia di Instalasi Rawat Inap Rumah Sakit Jiwa Ghrasia Yogyakarta [Internet]. Yogyakarta; 2014. Available from: <http://grhasia.jogjaprov.go.id/index.php/artikel/umum/142-analisis-efektivitas-biaya-penggunaan-terapi-antipsikotik-pada-pasien-skizofrenia-di-instalasi-rawat-inap-rumah-sakit-jiwa-grhasia-yogyakarta-bagian-i>
44. International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) [Internet]. World Health Organization. Malta; 2010. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22184833>
45. Barbui C, Signoretti A, Mule S, Boso M, Cipriani A. Does the addition of a second antipsychotic drug improve clozapine treatment? *Schizophr Bull*. 2009;35(2):458–68.
46. Centorrino F, Goren J, Hennen J, Salvatore P, Kelleher J, Baldessarini R. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. *Am J Psychiatry* [Internet]. 2004;161:700–6. Available from:

- [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list\\_uids=15056517](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15056517)
47. Fujimaki K, Takahashi T, Morinobu S. Association of typical versus atypical antipsychotics with symptoms and quality of life in schizophrenia. PLoS One. 2012;7(5).
48. Sweetman SC. Martindale: The Complete Drug Reference. 37th ed. London: Pharmaceutical Press; 2011.
49. Fatemi SH, Folsom TD. The neurodevelopmental hypothesis of Schizophrenia, revisited. Schizophr Bull. 2009;35(3):528–48.
50. Tjay TH, Rahardja K. Obat-Obat Penting. Jakarta: Elex Media Komputindo; 2002.
51. Food and Drug Administration. Abilify (Aripiprazole) [Internet]. USA; 2005. Available from: [http://www.accessdata.fda.gov/drugsatfda\\_docs/label/2005/021713s004,021436s007lbl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021713s004,021436s007lbl.pdf)
52. Lacy CF, Armstrong LL, Goldman NP, Lance LL. Drug Information Handbook. 18th ed. United States: American Pharmacist Association; 2009.
53. Clinical Drug Information. Clobazam [Internet]. 2015 [cited 2015 Jun 25]. Available from: <http://www.drugs.com/cdi/clobazam.html>
54. Texas Implementation of Medication Algorithms. Algoritma Antipsikotik TIMA. ISO Farmakoterapi. Jakarta: PT ISFI Penerbitan; 2009.